You are here:Home-Inhibitors & Agonists-GPCR-Adenosine Receptor

Request The Product List ofAdenosine Receptor Adenosine Receptor

Cat. No. Product Name CAS No. Information



AB928 (AB-928) is a potent, dual antagonist of the A2aR and A2bR adenosine receptors with Kb of 1.5 and 2.0 nM, respectively; displays high selectivity towards related receptors (A1R, A3R, CD73, CD39, NTPDase 2/3); AB928 is a potent inhibitor of NECA-mediated A2aR activation on cell lines, potently reverses adenosine-mediated CD8+ T cell suppression, potently inhibits cAMP-mediated pCREB activation in human leukocyte populations in whole blood; inhibits tumor micro-environment adenosine generation and signaling for the treatment of cancer.





2-Cl-IB-MECA (Chloro-IB-MECA, CF-102, Namodenoson) is a potent, selective A3 adenosine receptor agonist with Ki of 0.33 nM, 2500- and 1400-fold selectivity over A1 and A2a receptors; also displays 46,000-fold selectivity versus the Na(+)-independent adenosine transporter; inhibits adenylate cyclase via rat A3 receptors in CHO cells (IC50=67 nM); induces apoptosis in HL-60 cells at concentrations of <30 uM, significantly induced Ca(2+) release from intracellular Ca(2+) pools followed by Ca(2+) influx; increases plasma histamine concentrations in conscious rats.

Liver Cancer

Phase 2 Clinical



AZD-4635 (HTL 1071) is a potent, selective and orally available adenosine 2A receptor (A2AR) inhibitor with Ki of 1.7 nM, > 30-fold selectivity over other adenosine receptors; reverses the inhibitory effects of different concentrations of adenosine in CHO cells stably expressing human A2AR with IC50 of 0.1 nM (incubated with 0.1 uM adenosine); reverses suppression and restores IFNγ secretion in cells incubated with NECA in ex vivo CD8+ T cell assay; reduces tumor burden and enhances antitumor immunity in vivo.

Lung Cancer

Phase 2 Clinical



1337962-47-6 Taminadenant is an adenosine receptor A2a antagonist.


1541170-75-5 KH-176 (KH176, Sonlicromanol) is a smal molecule ROS-redox modulator, effectively reduces increased cellular ROS levels and protects OXPHOS deficient primary cells against redox perturbation by targeting the Thioredoxin/Peroxiredoxin system; significantly improves rotarod and gait performance and reduces the degeneration of retinal ganglion cells in Ndufs4 -/- mice, shows therapeutic effects in mammalian model of Leigh Disease.


183721-03-1 MRS1186 (MRS-1186) is a potent and selective human Adenosine A3 receptor (hA3AR) antagonist with Ki of 7.66 nM.


PBF509 (PBF-509, NIR 178) is a novel selective and potent Adenosine A2A Receptor (A2AR) antagonist, antagonizes A2AR agonist-mediated cAMP accumulation and impedance responses with KB values of 72.8 and 8.2 nM, respectively; PBF509 (orally) antagonized haloperidol-mediated catalepsy, reduced pilocarpine-induced tremulous jaw movements and potentiated the number of contralateral rotations induced by L-3,4-dihydroxyphenylalanine (L-DOPA) in unilaterally 6-OHDA-lesioned rats; PBF509 (3 mg/kg) inhibited L-DOPA-induced dyskinesia (LID), showing not only its efficacy on reversing parkinsonian motor impairments but also acting as antidyskinetic agent; increased responsiveness of human tumor-infiltrating lymphocytes when combined with anti-PD-1 or anti-PD-L1.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us